NASDAQ false 0001369568 0001369568 2024-05-21 2024-05-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 21, 2024

 

 

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

 

 

 

Delaware   001-33057   76-0837053
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		  

(I.R.S. Employer

Identification No.)

 

355 Alhambra Circle  
Suite 801  
Coral Gables, Florida   33134
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

  

Name of Exchange
on Which Registered

  

Ticker
Symbol

Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

At the Company’s 2024 Annual Meeting of Stockholders held on May 21, 2024 (“Annual Meeting”), Richard J. Daly, Patrick J. McEnany, Donald A. Denkhaus, Molly Harper, Charles B. O’Keeffe, Tamar Thompson, and David S. Tierney were elected to the Company’s Board of Directors (“Board”) to serve until the 2025 Annual Meeting of Stockholders or until their successor is duly elected and qualified, or until their earlier death, resignation or removal.

 

Item 5.07

Submission of Matters to a Vote of Security Holders

The final voting results on the matters considered at the Annual Meeting were as follows:

 

1.

Election of Directors:

 

Name   Votes For   Votes Against  

Votes

Abstained

   Broker Non-Votes

Richard J. Daly

   88,161,224   1,489,928   193,687   11,817,471

Patrick J. McEnany

   86,093,354   3,561,412   190,073   11,817,471

Donald A. Denkhaus

   85,937,799   3,717,631   189,409   11,817,471

Molly Harper

   86,018,457   3,637,844   188,538   11,817,471

Charles B. O’Keeffe

   84,926,089   4,730,350   188,400   11,817,471

Tamar Thompson

   85,049,382   4,604,945   190,512   11,817,471

David S. Tierney

   85,767,244   3,885,606   191,989   11,817,471

 

2.

Approval of an amendment to our 2018 Stock Incentive Plan:

 

Votes For

  

Votes Against

  

Votes Abstained

  

Broker Non-Votes

86,817,240   2,859,403   168,196   11,817,471

 

3.

Approval, on an advisory basis, of the 2023 compensation of our named executive officers:

 

Votes For

  

Votes Against

  

Votes Abstained

  

Broker Non-Votes

84,194,484   5,468,681   181,674   11,817,471

 

 

2

4.

Ratification of the selection of Grant Thornton, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:

 

Votes For

  

Votes Against

  

Votes Abstained

99,551,894   2,031,301   79,115

 

 

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Catalyst Pharmaceuticals, Inc.

By:

  

/s/ Michael Kalb

 

Michael Kalb

 

Executive Vice President and CFO

Dated: May 21, 2024

 

4

v3.24.1.1.u2
Document and Entity Information
May 21, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001369568
Document Type 8-K
Document Period End Date May 21, 2024
Entity Registrant Name CATALYST PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-33057
Entity Tax Identification Number 76-0837053
Entity Address, Address Line One 355 Alhambra Circle
Entity Address, Address Line Two Suite 801
Entity Address, City or Town Coral Gables
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33134
City Area Code (305)
Local Phone Number 420-3200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol CPRX
Entity Emerging Growth Company false
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Catalyst Pharmaceuticals.